26 research outputs found
ΠΡΠΎΠ³ΡΠ°ΠΌΠΌΠ° ΠΎΡΠ΅Π½ΠΊΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ ΠΈΠ·Π΄Π΅Π»ΠΈΠΉ Π΄Π»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΠΈΡΠΈΠ»ΠΈΡΠ°
The article presents quality monitoring data for over 300 batches of medical products for syphilis diagnostics performed by GNTsDK in 2003β2011. It was demonstrated that the result made it possible to ensure the necessary level of the diagnostic efficacy of medical products to be used in medical institutions in the Russian Federation for the purposes of syphilis diagnostics (clinical sensitivity and specificity: min. 95%, reproducibility of results: 100%). To ensure the quality of medical products for diagnosing sexually transmitted diseases including syphilis, FGBU GNTsDK (Ministry of Health Care of the Russian Federation) developed and implemented the Voluntary Quality Control Program for Medical Products for Diagnosing STDs in the Russian Federation in 2006. The Program provides for quality control for batches of medical products, centralized control and information about its results to heads of specialized dermatovenerological medical institutions engaged in syphilis diagnostics, and will also improve the quality of studies for the purposes of syphilis diagnostics using a controlled set of chemicals.ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΠ½Π³Π° ΠΊΠ°ΡΠ΅ΡΡΠ²Π° Π±ΠΎΠ»Π΅Π΅ 300 ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π΅Π½Π½ΡΡ
ΡΠ΅ΡΠΈΠΉ ΠΈΠ·Π΄Π΅Π»ΠΈΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ Π΄Π»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΠΈΡΠΈΠ»ΠΈΡΠ°, ΠΎΡΡΡΠ΅ΡΡΠ²Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΠΠΠ¦ΠΠ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ 2003β2011 Π³Π³. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°Ρ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ» ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΡΡ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΠ·Π΄Π΅Π»ΠΈΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ, ΠΏΡΠ΅Π΄Π½Π°Π·Π½Π°ΡΠ΅Π½Π½ΡΡ
Π΄Π»Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π² ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡΡ
Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ Ρ ΡΠ΅Π»ΡΡ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΡΠΈΡΠΈΠ»ΠΈΡΠ° (ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ Π½Π΅ Π½ΠΈΠΆΠ΅ 95%, Π²ΠΎΡΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² 100%). ΠΠ»Ρ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΡ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΈΠ·Π΄Π΅Π»ΠΈΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ Π΄Π»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ, ΠΏΠ΅ΡΠ΅Π΄Π°Π²Π°Π΅ΠΌΡΡ
ΠΏΠΎΠ»ΠΎΠ²ΡΠΌ ΠΏΡΡΠ΅ΠΌ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΡΠΈΡΠΈΠ»ΠΈΡΠ°, Π² Π€ΠΠΠ£ Β«ΠΠΠ¦ΠΠΒ» ΠΠΈΠ½Π·Π΄ΡΠ°Π²Π° Π ΠΎΡΡΠΈΠΈ Π² 2006 Π³. Π±ΡΠ»Π° ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΠΈ Π²Π½Π΅Π΄ΡΠ΅Π½Π° ΠΡΠΎΠ³ΡΠ°ΠΌΠΌΠ° Π΄ΠΎΠ±ΡΠΎΠ²ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΈΠ·Π΄Π΅Π»ΠΈΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ, ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΡ
Π΄Π»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΠΠΠ Π² Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ. Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΡ, ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²ΡΠ΅ΠΉ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π΅Π½Π½ΡΡ
ΡΠ΅ΡΠΈΠΉ ΠΈΠ·Π΄Π΅Π»ΠΈΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ, ΡΠ΅Π½ΡΡΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΈ ΡΠ΅Π³ΡΠ»ΡΡΠ½ΠΎΠ΅ ΠΈΠ½ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΎ Π΅Π³ΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°Ρ
ΡΡΠΊΠΎΠ²ΠΎΠ΄ΠΈΡΠ΅Π»Π΅ΠΉ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΉ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ²Π΅Π½Π΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ, ΠΎΡΡΡΠ΅ΡΡΠ²Π»ΡΡΡΠΈΡ
Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΡ ΡΠΈΡΠΈΠ»ΠΈΡΠ°, ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»Π° ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π΄Π»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΠΈΡΠΈΠ»ΠΈΡΠ° Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΠ΅ΠΌΡΡ
Π½Π°Π±ΠΎΡΠΎΠ² ΡΠ΅Π°Π³Π΅Π½ΡΠΎΠ²
ΠΠΊΡΠΏΠ΅ΡΡΠ½Π°Ρ ΠΏΠ°Π½Π΅Π»Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² Β«ΠΠ Π‘ΠΠ€ΠΠΠΠ‘Β» Π΄Π»Ρ ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΠΈΡΠΈΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ
GNTSD Rosmedtekhnologiy (State Research Center for Dermatology and Venereology of the Federal Agency for High-Technology Medical Aid) created a set of agents entitled "EP SYPHILIS expert panel of reference serums for serological diagnostics of syphilis" intended for internal laboratory and external quality control for these types of clinical laboratory tests. The expert panel includes four samples of reference materials: two samples containing the anti-T. pallidum antibody in high and low concentrations, and two other samples without the antibodies.
According to the international recommendations for production of biological standards and reference samples, EP SYPHILIS control materials are prepared in a native liquid form ready for administration; the materials are produced based on the human blood serum matrix.
The infection security of the control materials is ensured due to the preliminary examination of raw materials for the presence of markers of hemotransmissive infections (HIV and human B and C hepatitis) and thermal inactivation (within three hours at the temperature of 56 Π‘). The specific activity of these control materials during the warranty period (six months) is ensured by means of adding Proclean 300, a stabilizing agent (preservative), in the final concentration of 0.1%, and sterilizing filtration. Regular application of these control materials in clinical and diagnostics laboratories of health care institutions is aimed at standardization and improvement of the quality of tests intended for diagnostics of syphilis.ΠΡΠΈΠ²Π΅Π΄Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ Π² Π€ΠΠ£ Β«ΠΠΠ¦Π Π ΠΎΡΠΌΠ΅Π΄ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉΒ» Π½Π°Π±ΠΎΡΠ° ΡΠ΅Π°Π³Π΅Π½ΡΠΎΠ² Β«ΠΠΊΡΠΏΠ΅ΡΡΠ½Π°Ρ ΠΏΠ°Π½Π΅Π»Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΡΡΠ²ΠΎΡΠΎΡΠΎΠΊ Π΄Π»Ρ ΡΠ΅ΡΠΎΠ΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΠΈΡΠΈΠ»ΠΈΡΠ° Β«ΠΠ Π‘ΠΠ€ΠΠΠΠ‘Β», ΠΏΡΠ΅Π΄Π½Π°Π·Π½Π°ΡΠ΅Π½Π½ΠΎΠ³ΠΎ Π΄Π»Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ Π²Π½ΡΡΡΠΈΠ»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΈ Π²Π½Π΅ΡΠ½Π΅Π³ΠΎ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΡΠΊΠ°Π·Π°Π½Π½ΡΡ
Π²ΠΈΠ΄ΠΎΠ² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ. ΠΠΊΡΠΏΠ΅ΡΡΠ½Π°Ρ ΠΏΠ°Π½Π΅Π»Ρ Π²ΠΊΠ»ΡΡΠ°Π΅Ρ 4 ΠΎΠ±ΡΠ°Π·ΡΠ° ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ²: Π΄Π²Π° ΠΈΠ· Π½ΠΈΡ
ΡΠΎΠ΄Π΅ΡΠΆΠ°Ρ Π°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ T. pallidum Π² Π²ΡΡΠΎΠΊΠΎΠΉ ΠΈ Π½ΠΈΠ·ΠΊΠΎΠΉ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΠΈ Π΄Π²Π° Π΄ΡΡΠ³ΠΈΡ
Π΅ ΠΎΠ±ΡΠ°Π·ΡΠ° - Π½Π΅ ΡΠΎΠ΄Π΅ΡΠΆΠ°Ρ ΡΡΠΈ Π°Π½ΡΠΈΡΠ΅Π»Π°.
Π ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΠΌΠΈ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΡΠΌΠΈ ΠΏΠΎ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Ρ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ°Π½Π΄Π°ΡΡΠΎΠ² ΠΈ ΡΠ΅ΡΠ΅ΡΠ΅Π½ΡΠ½ΡΡ
ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΠ΅ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ Β«ΠΠ Π‘ΠΠ€ΠΠΠΠ‘Β» ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Ρ Π² Π½Π°ΡΠΈΠ²Π½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΠΉ ΡΠΎΡΠΌΠ΅ Π² Π³ΠΎΡΠΎΠ²ΠΎΠΌ ΠΊ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π²ΠΈΠ΄Π΅; ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΡΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΌΠ°ΡΡΠΈΡΡ ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ ΠΊΡΠΎΠ²ΠΈ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°.
ΠΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½Π°Ρ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°Π΅ΡΡΡ Π±Π»Π°Π³ΠΎΠ΄Π°ΡΡ ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΡΡΡΠ΅Π²ΡΡ
ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² Π½Π° Π½Π°Π»ΠΈΡΠΈΠ΅ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π³Π΅ΠΌΠΎΡΡΠ°Π½ΡΠΌΠΈΡΡΠΈΠ²Π½ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ (ΠΠΠ§ ΠΈ Π³Π΅ΠΏΠ°ΡΠΈΡΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° Π ΠΈ Π‘) ΠΈ ΡΠ΅ΡΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠ½Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ (ΠΏΡΠΈ 56 ΠΎΠ‘ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 3 Ρ.). Π‘ΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΡ
ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Π³Π°ΡΠ°Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΡΡΠΎΠΊΠ° Π³ΠΎΠ΄Π½ΠΎΡΡΠΈ (6 ΠΌΠ΅Ρ.) ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°Π΅ΡΡΡ ΠΏΡΡΠ΅ΠΌ Π΄ΠΎΠ±Π°Π²Π»Π΅Π½ΠΈΡ ΠΊ Π½ΠΈΠΌ ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·ΠΈΡΡΡΡΠ΅Π³ΠΎ (ΠΊΠΎΠ½ΡΠ΅ΡΠ²ΠΈΡΡΡΡΠ΅Π³ΠΎ) ΡΠ΅Π°Π³Π΅Π½ΡΠ° ΠΏΡΠΎΠΊΠ»ΠΈΠ½-300 Π² ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΠΉ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ 0,1 % ΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΡΠ΅ΡΠΈΠ»ΠΈΠ·ΡΡΡΠ΅ΠΉ ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ. Π Π΅Π³ΡΠ»ΡΡΠ½ΠΎΠ΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΡ
ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² Π² ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠΈΡΡ
ΡΡΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΉ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΎ Π½Π° ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΠΈΡ ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π΄Π»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΠΈΡΠΈΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ
Π ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΠΈΡΠΈΠ»ΠΈΡΠ°Π² Π΄Π΅ΡΠΌΠ°ΡΠΎΠ²Π΅Π½Π΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΡΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡΡ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ
The article presents the results of a cycle of external quality control of serological tests for diagnostics of the syphilitic infection
conducted by FGU GNTsD Rosmedtekhnologiy (State Research Center for Dermatology and Venereology of the Federal
Agency for High-Technology Medical Aid) in 2009 in 125 serology laboratories of dermatovenerological institutions in different
subjects of the Russian Federation. The authors evaluated the quality of serological tests (microprecipitation test, RPR, passive
hemagglutination test, immunofluorescence test and immune-enzyme assay) of four reference serum samples based on formal
and essential characteristics. The percentage of non-satisfactory results of studies for a set of reference serum samples in nontreponemal
tests (microprecipitation test and RPR) was 10.9%; in treponemal tests: in immune-enzyme assay - 1.4%, in passive
hemagglutination test - 1.2%, in immunofluorescence test - 0.9%. The most significant differences in the results were revealed
in studies of reference serum samples with the low content of antibodies (weakly positive) as well as those that contained no
antibodies to the syphilis causative agent.ΠΡΠΈΠ²Π΅Π΄Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΈΠΊΠ»Π° Π²Π½Π΅ΡΠ½Π΅Π³ΠΎ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π΄Π»Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΡΠΈΡΠΈΠ»ΠΈΡΠΈΡΠ΅-
ΡΠΊΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ, ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ³ΠΎ Π€ΠΠ£ Β«ΠΠΠ¦Π Π ΠΎΡΠΌΠ΅Π΄ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉΒ» Π² 2009 Π³. Π² 125 ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠΈΡΡ
Π΄Π΅ΡΠΌΠ°ΡΠΎ-
Π²Π΅Π½Π΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΉ ΡΡΠ±ΡΠ΅ΠΊΡΠΎΠ² Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ. ΠΡΠ΅Π½Π΅Π½ΠΎ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡ-
ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ (Π ΠΠ, RPR, Π ΠΠΠ, Π ΠΠ€ ΠΈ ΠΠ€Π) ΡΠ΅ΡΡΡΠ΅Ρ
ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ ΠΏΠΎ ΡΠΎΡΠΌΠ°Π»ΡΠ½ΡΠΌ ΠΈ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠ°ΠΌ. ΠΡΠΎΡΠ΅Π½Ρ Π½Π΅ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π½Π°Π±ΠΎΡΠ° ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΡΡΠ²ΠΎΡΠΎΡΠΎΠΊ Π² Π½Π΅ΡΡΠ΅ΠΏΠΎΠ½Π΅ΠΌΠ½ΡΡ
ΡΠ΅ΡΡΠ°Ρ
(Π ΠΠ ΠΈ RPR) ΡΠΎΡΡΠ°Π²ΠΈΠ» ΠΏΠΎ 10,9%; Π² ΡΡΠ΅ΠΏΠΎΠ½Π΅ΠΌΠ½ΡΡ
ΡΠ΅ΡΡΠ°Ρ
: Π² ΠΠ€Π - 1,4%, Π² Π ΠΠΠ - 1,2%, Π² Π ΠΠ€ - 0,9%. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅
Π·Π½Π°ΡΠΈΠΌΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π±ΡΠ»ΠΈ Π²ΡΡΠ²Π»Π΅Π½Ρ ΠΏΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΡΡΠ²ΠΎΡΠΎΡΠΊΠΈ Ρ Π½ΠΈΠ·ΠΊΠΈΠΌ ΡΠΎΠ΄Π΅ΡΠΆΠ°-
Π½ΠΈΠ΅ΠΌ Π°Π½ΡΠΈΡΠ΅Π» (ΡΠ»Π°Π±ΠΎΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΡ
), Π° ΡΠ°ΠΊΠΆΠ΅ Π½Π΅ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π²ΡΠΈΡ
Π°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Ρ ΡΠΈΡΠΈΠ»ΠΈΡΠ°
ΠΡΡΠΎΡΠΈΠ°ΡΠΈΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠΎΠ² Π² Π³Π΅Π½Π°Ρ TNFAIP3 ΠΈ TNIPI Ρ ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΡΡ ΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΡΠΎΡΠΈΠ°Π·Π° Π² ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ
Goal. To study polymorphisms in TNFAIP3 (rs610604) and TNIPI (rs17728338) genes in a sample of psoriasis patients and healthy volunteers from the Russian Federation. Materials and methods. By using allele specific hybridization methods in the form of real-time PCR and RFLP assay (Restriction Fragment Length Polymorphism), single-nucleotide polymorphisms of fragments of the following genes associated with predisposition to the development of psoriasis were studied in whole blood samples taken from psoriasis patients (n = 286) and healthy volunteers (n = 89): TNFAIP3 (rs610604) and TNIPI (rs17728338). Results. Psoriasis patients had a reliable increase in the frequency of the A/C heterozygous genotype of rs610604 polymorphism of the TNFAIP3 gene and A allele of rs17728338 polymorphism of the TNIP1 gene (A/G and A/A genotypes), which makes it possible to treat carriers of these genotypes as people with predisposition to the development of psoriasis, and to treat A/C genotypes of rs610604 polymorphism and A/G and A/A genotypes of rs17728338 polymorphism as predictors of the development of psoriasis in the Russian population. Conclusion. these data broaden the perception of genetic factors associated with the development of psoriasis in persons from the Russian population.Π¦Π΅Π»Ρ. ΠΠ·ΡΡΠΈΡΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΡ Π³Π΅Π½ΠΎΠ² TNFAIP3 (rs610604) ΠΈ TNIPI (rs17728338) Π² Π²ΡΠ±ΠΎΡΠΊΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ±ΡΠΎΠ²ΠΎΠ»ΡΡΠ΅Π² ΠΈΠ· Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ Π°Π»Π»Π΅Π»ΡΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠ±ΡΠΈΠ΄ΠΈΠ·Π°ΡΠΈΠΈ Π² ΡΠΎΡΠΌΠ°ΡΠ΅ ΠΠ¦Π Π² ΡΠ΅Π°Π»ΡΠ½ΠΎΠΌ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΠΈ ΠΠΠ Π€-Π°Π½Π°Π»ΠΈΠ·Π° (Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π΄Π»ΠΈΠ½Ρ ΡΠ΅ΡΡΡΠΈΠΊΡΠΈΠΎΠ½Π½ΡΡ
ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ²) Π² ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
ΠΎΡ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ (n = 286) ΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ±ΡΠΎΠ²ΠΎΠ»ΡΡΠ΅Π² (n = 89), Π±ΡΠ»ΠΈ ΠΈΠ·ΡΡΠ΅Π½Ρ ΠΎΠ΄Π½ΠΎΠ½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄Π½ΡΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΡ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ² Π³Π΅Π½ΠΎΠ², Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΡΡ ΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΡΠΎΡΠΈΠ°Π·Π°: TNFAIP3 (rs610604) ΠΈ TNIPI (rs17728338). Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠΎΡΡ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ Π³Π΅ΡΠ΅ΡΠΎΠ·ΠΈΠ³ΠΎΡΠ½ΠΎΠ³ΠΎ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° A/C ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° rs610604, Π³Π΅Π½Π° TNFAIP3 ΠΈ Π°Π»Π»Π΅Π»Ρ Π ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° rs17728338 Π³Π΅Π½Π° TNIP1 (Π³Π΅Π½ΠΎΡΠΈΠΏΡ A/G ΠΈ A/A), ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡ Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ Π΄Π°Π½Π½ΡΡ
Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ² ΠΊΠ°ΠΊ Π»ΠΈΡ Ρ ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΡΡ ΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΡΠΎΡΠΈΠ°Π·Π°, Π° Π³Π΅Π½ΠΎΡΠΈΠΏΡ A/Π‘ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° rs610604, A/G ΠΈ A/A ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° rs17728338 β ΠΊΠ°ΠΊ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΡΠΎΡΠΈΠ°Π·Π° Π² ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΡΠ°ΡΡΠΈΡΡΡΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΠΊΡΠΎΡΠ°Ρ
, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ ΠΏΡΠΎΡΠΈΠ°Π·Π°, Ρ Π»ΠΈΡ ΠΈΠ· ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ
Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΈ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ° ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ ΠΏΠΎ ΠΏΡΠ΅Π΄ΡΠΏΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π² ΠΡΡ Π°Π½Π³Π΅Π»ΡΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ
Goal of the study. To assess the efficacy of a complex of preventive measures developed in 2011-2012 for preventing the propagation of gonococcal infection in the Arkhangelsk region based on a study of the gonococcal infection morbidity dynamics in the territory of the region in 2011-2013. Study materials and methods: the authors analyzed statistics on the gonococcal infection morbidity in the territory of the Arkhangelsk region. To assess the efficacy of the complex of measures developed to prevent the propagation of gonococcal infection and other STDs in the Arkhangelsk region, the morbidity dynamics rate was calculated. Results. A complex of preventive measures for preventing the propagation of gonococcal infection in the Arkhangelsk region was developed in 2011 and was put to practical use in 2012. In 2012, the gonococcal infection morbidity rate grew in the Arkhangelsk region by 49.1% vs. 2011. Such a growth can be explained by the improved procedures for recording cases of gonococcal infection used in departmental and private medical organizations as well as optimization of the infection diagnostics methods including cultural tests and PCR, in particular, in women. In 2013, the incidence of gonococcal infection fell down as compared to 2012 (85.3 cases per 100,000 people in 2012 and 68.6 cases in 2013) including among teenagers (76.9 cases per 100,000 people in 2012 and 52.9 cases in 2013) in most municipal districts of the Arkhangelsk region (in 20 districts and towns, or 76.9% of the territory). Conclusions. Practical implementation of the complex of preventive measures developed to prevent the propagation of gonococcal infection and other STDs in the Arkhangelsk region substantially reduced the morbidity of gonococcal infection in the territory of the region. The collected data are sufficient to give a positive assessment of the developed measures and emphasize their contribution to the reduction of the morbidity of gonococcal infection.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΡΠ΅Π½ΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΠΎΠ³ΠΎ Π² 2011-2012 Π³Π³. ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ° ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ ΠΏΠΎ ΠΏΡΠ΅Π΄ΡΠΏΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π² ΠΡΡ
Π°Π½Π³Π΅Π»ΡΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ Π½Π° ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠΈ ΠΎΠ±Π»Π°ΡΡΠΈ Π² 2011-2013 Π³Π³. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ Π½Π° ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠΈ ΠΡΡ
Π°Π½Π³Π΅Π»ΡΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ. ΠΠ»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ° ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ ΠΏΠΎ ΠΏΡΠ΅Π΄ΡΠΏΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈ Π΄ΡΡΠ³ΠΈΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ, ΠΏΠ΅ΡΠ΅Π΄Π°Π²Π°Π΅ΠΌΡΡ
ΠΏΠΎΠ»ΠΎΠ²ΡΠΌ ΠΏΡΡΠ΅ΠΌ (ΠΠΠΠ), Π² ΠΡΡ
Π°Π½Π³Π΅Π»ΡΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ ΡΠ°ΡΡΡΠΈΡΡΠ²Π°Π»ΡΡ ΡΠ΅ΠΌΠΏ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠΌΠΏΠ»Π΅ΠΊΡ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ ΠΏΠΎ ΠΏΡΠ΅Π΄ΡΠΏΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π² ΠΡΡ
Π°Π½Π³Π΅Π»ΡΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ Π±ΡΠ» ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½ Π² 2011 Π³. ΠΈ Π²Π½Π΅Π΄ΡΠ΅Π½ Π² ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ Π² 2012 Π³. ΠΠΎ Π΄Π°Π½Π½ΡΠΌ 2012 Π³., Π² ΠΡΡ
Π°Π½Π³Π΅Π»ΡΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ Π±ΡΠ» ΠΎΡΠΌΠ΅ΡΠ΅Π½ ΡΠΎΡΡ Π½Π° 49,1% Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ 2011 Π³., ΡΡΠΎ ΠΌΠΎΠ³Π»ΠΎ Π±ΡΡΡ ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½ΠΎ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΈ ΡΠ»ΡΡΠ°Π΅Π² Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π² Π²Π΅Π΄ΠΎΠΌΡΡΠ²Π΅Π½Π½ΡΡ
ΠΈ ΡΠ°ΡΡΠ½ΡΡ
ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡΡ
ΠΈ ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠ΅ΠΉ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ ΠΊΡΠ»ΡΡΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅Π½Π½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ, Π² ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Ρ ΠΆΠ΅Π½ΡΠΈΠ½. Π² 2013 Π³. Π² Π°Π±ΡΠΎΠ»ΡΡΠ½ΠΎΠΌ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ (Π² 20 ΡΠ°ΠΉΠΎΠ½Π°Ρ
ΠΈ Π³ΠΎΡΠΎΠ΄Π°Ρ
- 76,9% ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠΉ) ΠΌΡΠ½ΠΈΡΠΈΠΏΠ°Π»ΡΠ½ΡΡ
ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ ΠΡΡ
Π°Π½Π³Π΅Π»ΡΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ 2012 Π³. (Π² 2012 Π³. - 85,3 ΡΠ»ΡΡΠ°Ρ Π½Π° 100 000 Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ, Π² 2013 Π³. - 68,6), Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΡΡΠ΅Π΄ΠΈ ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ² (Ρ 76,9 Π½Π° 100 000 Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π² 2012 Π³. Π΄ΠΎ 52,9 - Π² 2013 Π³.). ΠΡΠ²ΠΎΠ΄Ρ. Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΠ΅ Π² ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ° ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ ΠΏΠΎ ΠΏΡΠ΅Π΄ΡΠΏΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈ Π΄ΡΡΠ³ΠΈΡ
ΠΠΠΠ Π² ΠΡΡ
Π°Π½Π³Π΅Π»ΡΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ ΠΊ 2013 Π³. ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΡΠ½ΠΈΠ·ΠΈΡΡ ΡΡΠΎΠ²Π΅Π½Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ Π½Π° ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠΈ ΠΎΠ±Π»Π°ΡΡΠΈ. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΎΡΠ΅Π½ΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΡ
ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠΉ ΠΈ ΠΎΡΠΌΠ΅ΡΠΈΡΡ ΠΈΡ
Π²ΠΊΠ»Π°Π΄ Π² ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΠΈ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ
ΠΠΠ«Π’ ΠΠΠΠΠΠ£ΠΠ―Π ΠΠΠΠ Π’ΠΠΠΠ ΠΠΠΠΠΠ― Π Π€ΠΠΠΠΠΠΠΠ’ΠΠ§ΠΠ‘ΠΠΠΠ ΠΠΠΠΠΠΠ Π¨Π’ΠΠΠΠΠ N. GONORRHOEAE Π Π ΠΠ‘Π‘ΠΠΠ‘ΠΠΠ Π€ΠΠΠΠ ΠΠ¦ΠΠ
The article presents results of the molecular typing and phylogenetic analysis of N. Gonorrhoeae strains in the Russian Federation conducted based on a large sample of N. Gonorrhoeae strains. A considerable genetic variety of N. Gonorrhoeae strains circulating in the territory of the Russian Federation was revealed, which can serve as an evidence of a high rate of accumulation of por and tbp gene mutations among the Russian population of N. Gonorrhoeae strains. The authors established the genetic relationship between individual sequence types of N. Gonorrhoeae strains, and revealed total and dominating sequence types of N. Gonorrhoeae strains found both in different territories of the Russian Federation and abroad, which confirms that such strains can be transferred between different territories of the Russian Federation and from abroad due to active migration of population.ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΡΠΈΠ»ΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΡΡΠ°ΠΌΠΌΠΎΠ² N. gonorrhoeae Π² Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ, ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΠ΅ Π½Π° Π±ΠΎΠ»ΡΡΠΎΠΉ Π²ΡΠ±ΠΎΡΠΊΠ΅ ΡΡΠ°ΠΌΠΌΠΎΠ² N. gonorrhoeae. ΠΡΡΠ²Π»Π΅Π½ΠΎ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·ΠΈΠ΅ ΡΡΠ°ΠΌΠΌΠΎΠ² N. gonorrhoeae, ΡΠΈΡΠΊΡΠ»ΠΈΡΡΡΡΠΈΡ
Π½Π° ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠΈ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ, ΡΡΠΎ ΠΌΠΎΠΆΠ΅Ρ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΠΎΠ²Π°ΡΡ ΠΎ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΠΊΠΎΡΠΎΡΡΠΈ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΉ Π³Π΅Π½ΠΎΠ² por ΠΈ tbp ΡΡΠ΅Π΄ΠΈ ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ ΡΡΠ°ΠΌΠΌΠΎΠ² N. gonorrhoeae. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π±Π»ΠΈΠ·ΠΎΡΡΡ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ
ΡΠΈΠΊΠ²Π΅Π½Ρ-ΡΠΈΠΏΠΎΠ² ΡΡΠ°ΠΌΠΌΠΎΠ² N. gonorrhoeae, Π²ΡΡΠ²Π»Π΅Π½Ρ ΠΎΠ±ΡΠΈΠ΅ ΠΈ Π΄ΠΎΠΌΠΈΠ½ΠΈΡΡΡΡΠΈΠ΅ ΡΠΈΠΊΠ²Π΅Π½Ρ-ΡΠΈΠΏΡ ΡΡΠ°ΠΌΠΌΠΎΠ² N. gonorrhoeae, ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠ΅ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π½Π° ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΡΡ
Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ, Π½ΠΎ ΠΈ Π·Π° ΡΡΠ±Π΅ΠΆΠΎΠΌ, ΡΡΠΎ ΠΌΠΎΠΆΠ΅Ρ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΠΎΠ²Π°ΡΡ ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠ° ΡΡΠΈΡ
ΡΡΠ°ΠΌΠΌΠΎΠ² ΠΌΠ΅ΠΆΠ΄Ρ ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΡΠΌΠΈ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ ΠΈ Π² Π ΠΎΡΡΠΈΠΉΡΠΊΡΡ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΡ ΠΈΠ·-Π·Π° ΡΡΠ±Π΅ΠΆΠ° Π·Π° ΡΡΠ΅Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΌΠΈΠ³ΡΠ°ΡΠΈΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΊ ΠΏΡΠΎΡΠΈΠ°Π·Ρ ΡΡΠ΅Π΄ΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ
Goal. To assess the incidence of genes predisposing to the development of psoriasis based on selected molecular and genetic study methods among the Russian population. Materials and methods. By using allele specific hybridization methods in the form of real-time PCR and RFLP assay (Restriction Fragment Length Polymorphism), single-nucleotide polymorphisms of fragments of 13 genes associated with predisposition to the development of psoriasis were studied in whole blood samples obtained from 45 psoriatic patients: rs4649203 (gene IL-28RA), rs11209026 (gene IL-23R), rs610604 (gene TNFAIP3), rs514315 (gene SERPINB8), rs9304742 (gene ZNF816A), rs17728338 (gene TNIP1), rs13190932 (gene TRAF3IP2), rs2235617 (gene ZNF313), rs27524 (gene ERAP1), rs702873 (gene REL), rs3213094 (gene IL-12B), rs12720356 (gene TYK2), and rs8016947 (gene NFKBI). Results. A set of data on the genotype structure and incidence in respective loci of 13 genes associated with predisposition to develop psoriasis was obtained for the first time based on a Russian sample of patients. At this stage of the study, we failed to reveal any reliable differences concerning the incidence of individual genotypes between psoriatic patients and healthy people because of the small size of the sample. Gene TYK2 (rs1272035) served as an exclusion. The homozygous T/T genotype was revealed more often (p < 0.01) in psoriatic patients (95.6%) vs. healthy people (77.8%), which makes it possible to consider the carriers of this genotype as people predisposed to the development of psoriasis.Π¦Π΅Π»Ρ. ΠΡΠ΅Π½ΠΊΠ° ΡΠ°ΡΡΠΎΡΡ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ Π² ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ Π³Π΅Π½ΠΎΠ² ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΊ ΠΏΡΠΎΡΠΈΠ°Π·Ρ Π²ΡΠ±ΡΠ°Π½Π½ΡΠΌΠΈ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ Π°Π»Π»Π΅Π»Ρ-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π³ΠΈΠ±ΡΠΈΠ΄ΠΈΠ·Π°ΡΠΈΠΈ Π² ΡΠΎΡΠΌΠ°ΡΠ΅ ΠΠ¦Π Π² ΡΠ΅Π°Π»ΡΠ½ΠΎΠΌ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΠΈ ΠΠΠ Ρ-Π°Π½Π°Π»ΠΈΠ·Π° (Π°Π½Π°Π»ΠΈΠ· ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΠ° Π΄Π»ΠΈΠ½Ρ ΡΠ΅ΡΡΡΠΈΠΊΡΠΈΠΎΠ½Π½ΡΡ
ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ²) Π² ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΡ
ΠΎΡ 45 Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ, Π±ΡΠ»ΠΈ ΠΈΠ·ΡΡΠ΅Π½Ρ ΠΎΠ΄Π½ΠΎΠ½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄Π½ΡΠ΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌΡ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ² 13-ΠΈ Π³Π΅Π½ΠΎΠ², Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΡΡ ΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΡΠΎΡΠΈΠ°Π·Π°: rs4649203 (Π³Π΅Π½ IL-28RA), rs11209026 (Π³Π΅Π½ IL-23R), rs610604 (Π³Π΅Π½ TNFAIP3), rs514315 (Π³Π΅Π½ SERPINB8), rs9304742 (Π³Π΅Π½ ZNF816A), rs17728338 (Π³Π΅Π½ TNIP1), rs13190932 (Π³Π΅Π½ TRAF3IP2), rs2235617 (Π³Π΅Π½ ZNF313), rs27524 (Π³Π΅Π½ ERAP1), rs702873 (Π³Π΅Π½ REL), rs3213094 (Π³Π΅Π½ IL-12B), rs12720356 (Π³Π΅Π½ TYK2), rs8016947 (Π³Π΅Π½ NFKBI). Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΏΠ΅ΡΠ²ΡΠ΅ Π½Π° ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π²ΡΠ±ΠΎΡΠΊΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΠΎΠ»ΡΡΠ΅Π½ ΠΌΠ°ΡΡΠΈΠ² Π΄Π°Π½Π½ΡΡ
ΠΎ ΡΡΡΡΠΊΡΡΡΠ΅ ΠΈ ΡΠ°ΡΡΠΎΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ² Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΡΡΡΠΈΡ
ΠΏΠΎΠ·ΠΈΡΠΈΡΡ
13 Π³Π΅Π½ΠΎΠ², Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΡΡ ΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΡΠΎΡΠΈΠ°Π·Π°. ΠΠ° Π΄Π°Π½Π½ΠΎΠΌ ΡΡΠ°ΠΏΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΡ
ΠΎΡΠ»ΠΈΡΠΈΠΉ Π² ΡΠ°ΡΡΠΎΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ
Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ² ΠΌΠ΅ΠΆΠ΄Ρ Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΠΌΠΈ Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π½Π΅ Π±ΡΠ»ΠΎ Π²Π²ΠΈΠ΄Ρ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΌΠ°Π»ΠΎΡΠΈΡΠ»Π΅Π½Π½ΠΎΡΡΠΈ Π²ΡΠ±ΠΎΡΠΊΠΈ. ΠΡΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΎΡΡΠ°Π²ΠΈΠ» Π³Π΅Π½ TYK2 (rs1272035). ΠΠΎΠΌΠΎΠ·ΠΈΠ³ΠΎΡΠ½ΡΠΉ Π’/Π’ Π³Π΅Π½ΠΎΡΠΈΠΏ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΠ°ΡΠ΅ (Ρ < 0,01) Π²ΡΡΡΠ΅ΡΠ°Π»ΡΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ (95,6%) Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ ΡΠΎ Π·Π΄ΠΎΡΠΎΠ²ΡΠΌΠΈ (77,8%), ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡ Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ Π΄Π°Π½Π½ΠΎΠ³ΠΎ Π³Π΅Π½ΠΎΡΠΈΠΏΠ° ΠΊΠ°ΠΊ Π»ΠΈΡ Ρ ΠΏΡΠ΅Π΄ΡΠ°ΡΠΏΠΎΠ»ΠΎΠΆΠ΅Π½Π½ΠΎΡΡΡΡ ΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΡΠΎΡΠΈΠ°Π·Π°